<DOC>
	<DOC>NCT00437554</DOC>
	<brief_summary>Primary: To show the equivalence in terms of efficacy glycated hemoglobin (HbA1c) of glimepiride/metformin slow-release combination tablet (Amaryl M SR 2/500) once daily compared with fixed-dose glimepiride/metformin combination tablet (Amaryl M 1/250) twice a day on HbA1c in patients with type 2 Diabetes Mellitus (DM) Secondary: To compare the following parameters in two treatment arm - Efficacy; Fasting Plasma Glucose (FPG) and Post-prandial two hours plasma glucose (PP2h) - Response rates in terms of HbA1c, FPG - Patient compliance Safety: - episodes of hypoglycemia - adverse events - laboratory values including hematology blood chemistry and urinalysis - vital sign and physical examination</brief_summary>
	<brief_title>Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects with type 2 DM diagnosed for at least 3 months but no longer than 10 years before screening; BMI ≤ 40 kg/m²; A negative pregnancy test for all females of childbearing potential A history of acute metabolic complications such as diabetic ketoacidosis or hyperosmolar nonketotic coma within 3 months before screening; Current therapy with any oral antidiabetic drugs or previous use in the 4 weeks other than sulfonylureas or metformin (8 weeks in case of thiazolidinedione) before screening; Concomitant treatment prohibited during the study period; Any oral antidiabetic drugs other than study medication Any insulin therapy over 7 days consecutively or intermittently in order to treat acute metabolic decompensation or systemic infection during the study Intermittent use of systemic corticosteroids or large dose of inhaled steroids Subjects with clinically significant renal (serum creatinine level &gt;1.5 mg/dL in male and &gt;1.4 mg/dL in female) or hepatic disease (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &gt;2x upper limit of normal (ULN)); Subjects with acute and severe cardiovascular disease (e.g. heart failure, myocardiac infarction, stroke etc.) Clinically significant laboratory abnormality on screening labs or any medical condition that would affect the completion or outcome of the study in the opinion of the investigator and/or sponsor; Pregnant or lactating females; History of drug or alcohol abuse; Subjects with known hypersensitivity to glimepirides, or metformin; Nightshift workers; Treatment with any investigational product in the last 3 months before study entry; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>